Hosts Mitsuaki Sawano, MD, Shun Kohsaka, MD, and Satoshi Shoji, MD, highlight two JACC papers simultaneously published at ESC 2025. Twice-A-Day Clopidogrel vs Ticagrelor to Reduce Short-Term MACE after Primary PCI: The TADCLOT Trial tested whether ticagrelor is superior to high-dose clopidogrel in reducing 30-day MACE after primary PCI for STEMI. While no difference was observed at 30 days, ticagrelor showed a signal for early ischemic protection at 7 and 14 days without excess bleeding. Personalized or Standard Duration of Dual Antiplatelet Therapy after PCI: The PARTHENOPE Trial compared risk score–guided DAPT durations (3, 6, or 24 months) against the standard 12-month strategy in over 2,000 PCI patients. Personalized therapy reduced NACE at 24 months, driven by fewer ischemic events, with no excess in bleeding.

Ver todos los episodios